Intuitive Surgical reported strong Q1 2026 results, surpassing both earnings per share (EPS) and revenue expectations. The company also slightly raised its guidance for 2026, reflecting confidence in its growth prospects. Despite a high valuation relative to its expected EPS growth, Intuitive Surgical's dominant position in the robotic surgery market and substantial R&D investment support its competitive moat. The analyst maintains a Hold rating, preferring more valuation safety before buying.
In Q2 2026, AMD's stock surged 182.4%, driven by growth in AI workloads linked to large language models. CrowdStrike also saw strong gains of 95.6% due to a positive shift in the AI investment narrative. Conversely, Netflix's stock declined after bea...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
